Dinosaur the size of a Labrador discovered in US after misclassification
Believed to have lived approximately 150 million years ago, Enigmacursor was a herbivore roughly the size of a Labrador with long legs for escaping predators.
The fossils, discovered between 2021 and 2022 in the western United States, were bought by the Natural History Museum from a commercial dealer.
Palaeontologists realised the near-complete skeleton was not a Nanosaurus, as originally labelled, leading to its reclassification as a distinct species, Enigmacursor, meaning "mysterious runner."
This discovery offers hope for correctly identifying hundreds of other small dinosaur bones previously misclassified and highlights the need to re-evaluate historical assumptions in palaeontology.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News
an hour ago
- Sky News
AI used to design antibiotics that can combat drug-resistant superbugs gonorrhoea and MRSA
Why you can trust Sky News New antibiotics that could kill drug-resistant gonorrhoea and MRSA have been developed with the help of artificial intelligence (AI), researchers have said. A team at Massachusetts Institute of Technology (MIT) used generative AI algorithms to design more than 36 million possible compounds. Once computationally screened for antimicrobial properties, the top candidates were shown to be structurally different from any existing antibiotics. They also seemed to work in a new way - by disrupting bacterial cell membranes. Antibiotics kill bacteria, but some infections have become resistant to drugs. It is estimated that drug-resistant bacterial infections cause nearly 5 million deaths per year worldwide. Two compounds were found to be effective against gonorrhoea and MRSA infections - namely NG1 and DN1 respectively. A non-profit organisation is now working on modifying the compounds to make them suitable for further testing. The research appeared on Thursday in scientific journal Cell. MIT Professor James Collins, the paper's senior author, said: "We're excited about the new possibilities that this project opens up for antibiotics development. "Our work shows the power of AI from a drug design standpoint, and enables us to exploit much larger chemical spaces that were previously inaccessible." This could re-energise the drug pipeline just in time Could AI save us from the antibiotic apocalypse? That's the hope from new research in which scientists designed novel drugs atom-by-atom to beat two notorious superbugs, including MRSA. Antibiotic resistance is a growing problem, causing the deaths of around 5 million people a year. Even routine operations could become life-threatening events in future - unless a new generation of antibiotics can be found. Enter the data crunching power of artificial intelligence. Researchers at the Massachusetts Institute of Technology used generative AI to design millions of possible compounds that don't exist or haven't yet been discovered by science - and then screened them for likely activity against bacteria, as well as toxicity in human cells. The top candidates were structurally unlike any existing antibiotics and appeared to work in completely novel ways to disrupt the membranes of bacterial cells. Tests on bacteria in lab dishes and infected mice identified two possible antibiotics against MRSA and the bacteria that causes gonorrhoea. There would be many years of further testing, including clinical trials, before the drugs would be prescribed by doctors. But the new approach could prove significant. The last major class of antibiotics was discovered in the 1980s. There have been tweaks to the drugs since, but that only slowed the development of resistance. Many pharmaceutical companies have given up on antibiotic development, daunted by the challenge and the cost. Using AI could take out some of the risk of failure. And that might re-energise the drug pipeline just in time. One of the study's lead authors, MIT postdoc Aarti Krishnan, said: "We wanted to get rid of anything that would look like an existing antibiotic, to help address the antimicrobial resistance crisis in a fundamentally different way.
The Guardian
an hour ago
- The Guardian
Trump cuts to science research threaten his administration's own AI action plan
The Trump administration released 'America's AI Action Plan' last month with the goal of expanding US dominance when it comes to AI in order to maintain a global edge, especially over China. But Donald Trump's cuts to scientific research funding through federal agencies – including the National Intitute Health, the National Science Foundation, the Defense Advanced Research Projects Agency and Nasa – will undermine that goal and threaten the research environment that fostered the foundations of AI, experts in the field said. Mark Histed, chief of neural computation and behavior at NIH, said that while the effects of funding cuts on AI might not be obvious in the next year or two, they threaten 'the whole ecosystem that we have built around AI, that has been created by federal support'. 'What I see is an ecosystem, right? I see multiple different disciplines contributing different aspects to this process. I see academia playing a key role and industry playing a key role. And so as we look forward and we think about trying to advance AI, we need to be supporting that entire ecosystem,' Rebecca Willett, a computer science professor at the University of Chicago and faculty director of AI at the Data Science Institute, explained, echoing Histed. Histed and Willett both believe that AI simply would not exist in its current form without federally funded research, and offered a variety of AI technologies and companies that owe their development to federal funding. For example, self-driving cars rely on computer vision technology – federal funding has supported its development since the 1980s. Computer vision is the foundation for the vast majority of face and image recognition technologies. AlphaFold, which uses AI to help discover new medications, and Anthropic, which improves AI safety, including for the US Department of Defense, also exists thanks to federal support. AI research often takes cues from other realms of science, which in turn can help foster AI, so cuts to other disciplines will affect the intelligence's development. Histed points to the overlap between his field of neuroscience and AI. 'We're just at the beginning of understanding how networks of connected neurons create functions like memory and cognition. And if you look at a machine learning network or an AI network, that is also the case,' he said. Histed pointed out that federally funded research that brings these disciplines together has led to Nobel prize-winning work. Geoffrey Hinton and John Hopfield won the 2024 Nobel prize in physics for their work at the intersection of neuroscience and AI, and received support from the NSF. Trump's plan could also pose a threat to AI safety, which is essential to ensuring that AI is not only effective but that it operates within the boundaries of the law. The plan includes provisions to revise guidelines at the National Institute of Standards and Technology 'to eliminate references to misinformation, Diversity, Equity, and Inclusion, and climate change'. These are three of the most controversial aspects of AI, which has been demonstrated to show gender and racial bias in a variety of applications, including face recognition technology and popular applications like ChatGPT. A recent study found that ChatGPT advises women to ask for less money than men when prompted for advice about salary expectations. Histed says that the field of AI safety is also closely linked with neuroscience, because understanding how human neural networks create bias can also help us understand how AI networks create bias. Sign up to This Week in Trumpland A deep dive into the policies, controversies and oddities surrounding the Trump administration after newsletter promotion Trump's plan also calls for less red tape when it comes to building AI datacentres that can suck up huge amounts of energy. Willett said it was true that large-scale machine learning systems 'come at an enormous cost. It's a huge amount of energy, a huge amount of cooling.' But, she added, AI companies themselves should still want to reduce those costs regardless of what Trump's plan says. 'Not only do they have environmental impacts, but it's expensive for the companies that are running these systems. And so I think across the AI community, people are invested in trying to make these systems more efficient,' Willett said. Willett and Histed both say that the AI community will be under threat in the coming years if the federal government no longer funds their training at universities. Histed noted that the federally funded 'talent pipeline' is 'incredibly important', adding 'we train lots and lots and lots of people in neuroscience and related fields that are going directly to these tech companies. There's tons of overlap. All the people who are leading the technical side of the AI revolution have had contact with the academic world that trained them and is supported by US federal funding. 'One of the big ways in which tech companies benefit from universities is that we train students, right?' Willett said. 'And so they walk into these companies with cutting-edge skills that these companies need. And so right off the bat, I think universities are playing an essential role that's important to industry.'
Reuters
3 hours ago
- Reuters
Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI
Aug 14 (Reuters) - Eli Lilly (LLY.N), opens new tab has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases. Lilly currently dominates the obesity treatment market, which is estimated to be worth $150 billion by the next decade, and is trying to strengthen its foothold in the space through the development of next-generation drugs, acquisitions and partnerships. The deal gives Lilly access to Superluminal's proprietary artificial-intelligence-driven platform to rapidly discover potential drug candidates targeting G-protein-coupled receptors (GPCR) - a class of proteins that can influence a range of physiological processes including metabolism, cell growth and immune responses - the drug developer said on Thursday. In a similar move, Danish rival Novo Nordisk ( opens new tab struck a $2.2 billion deal with U.S. biotech Septerna in May to develop oral small-molecule medicines targeting GPCRs for obesity and other cardiometabolic diseases. Lilly has been capitalizing on the overwhelming popularity of the GLP-1 class of medicines, which includes its blockbuster drug Zepbound as well as Novo's Wegovy. It is also developing a keenly watched oral GLP-1 drug, orforglipron, which has failed to meet investors' lofty expectations. The drugmaker teamed up with Hong Kong-listed biotech Laekna ( opens new tab last year to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle. Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's platform, the drug developer said. As part of the deal, Superluminal is eligible to receive upfront and milestone payments, an equity investment as well as tiered royalties on net sales, the company said. Boston-based startup Superluminal is developing a wholly owned lead candidate targeting a protein called melanocortin 4 receptor to treat certain rare, genetic forms of obesity and is expected to begin human trials next year. The lead candidate is not part of the deal with Lilly. Superluminal is backed by investors including RA Capital Management, Insight Partners and NVentures, NVIDIA's venture capital arm.
